These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 37279408)

  • 1. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
    Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
    J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
    Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin MD; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
    NEJM Evid; 2022 Jul; 1(7):EVIDoa2200006. PubMed ID: 38319255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Niemann CU; Munir T; Moreno C; Owen C; Follows GA; Benjamini O; Janssens A; Levin MD; Robak T; Simkovic M; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Sinet P; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Kater AP
    Lancet Oncol; 2023 Dec; 24(12):1423-1433. PubMed ID: 37944541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
    Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
    J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
    J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M; Kater AP; Robrecht S; von Tresckow J; Zhang C; Gregor M; Thornton P; Staber PB; Tadmor T; Lindström V; Juliusson G; Janssens A; Levin MD; da Cunha-Bang C; Schneider C; Goldschmidt N; Vandenberghe E; Rossi D; Benz R; Nösslinger T; Heintel D; Poulsen CB; Christiansen I; Frederiksen H; Enggaard L; Posthuma EFM; Issa DE; Visser HPJ; Bellido M; Kutsch N; Dürig J; Stehle A; Vöhringer M; Böttcher S; Schulte C; Simon F; Fink AM; Fischer K; Holmes EE; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Stilgenbauer S; Hallek M; Niemann CU; Eichhorst B
    Lancet Oncol; 2024 Jun; 25(6):744-759. PubMed ID: 38821083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.
    Kater AP; Wu JQ; Kipps T; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Dubois J; Eldering E; Mellink C; Van Der Kevie-Kersemaekers AM; Kim SY; Chyla B; Punnoose E; Bolen CR; Assaf ZJ; Jiang Y; Wang J; Lefebure M; Boyer M; Humphrey K; Seymour JF
    J Clin Oncol; 2020 Dec; 38(34):4042-4054. PubMed ID: 32986498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
    Seymour JF; Kipps TJ; Eichhorst BF; D'Rozario J; Owen CJ; Assouline S; Lamanna N; Robak T; de la Serna J; Jaeger U; Cartron G; Montillo M; Mellink C; Chyla B; Panchal A; Lu T; Wu JQ; Jiang Y; Lefebure M; Boyer M; Kater AP
    Blood; 2022 Aug; 140(8):839-850. PubMed ID: 35605176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
    Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
    N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
    Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
    Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
    Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
    Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
    Scarfò L; Heltai S; Albi E; Scarano E; Schiattone L; Farina L; Moia R; Deodato M; Ferrario A; Motta M; Reda G; Sancetta R; Coscia M; Rivela P; Laurenti L; Varettoni M; Perotta E; Capasso A; Ranghetti P; Colia M; Ghia P
    Blood; 2022 Dec; 140(22):2348-2357. PubMed ID: 35921541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
    Al-Sawaf O; Zhang C; Jin HY; Robrecht S; Choi Y; Balasubramanian S; Kotak A; Chang YM; Fink AM; Tausch E; Schneider C; Ritgen M; Kreuzer KA; Chyla B; Paulson JN; Pallasch CP; Frenzel LP; Peifer M; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
    Nat Commun; 2023 Apr; 14(1):2147. PubMed ID: 37072421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    Eichhorst B; Niemann CU; Kater AP; Fürstenau M; von Tresckow J; Zhang C; Robrecht S; Gregor M; Juliusson G; Thornton P; Staber PB; Tadmor T; Lindström V; da Cunha-Bang C; Schneider C; Poulsen CB; Illmer T; Schöttker B; Nösslinger T; Janssens A; Christiansen I; Baumann M; Frederiksen H; van der Klift M; Jäger U; Leys MBL; Hoogendoorn M; Lotfi K; Hebart H; Gaska T; Koene H; Enggaard L; Goede J; Regelink JC; Widmer A; Simon F; De Silva N; Fink AM; Bahlo J; Fischer K; Wendtner CM; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Levin MD; van Oers M; Geisler C; Stilgenbauer S; Hallek M;
    N Engl J Med; 2023 May; 388(19):1739-1754. PubMed ID: 37163621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
    Huber H; Edenhofer S; von Tresckow J; Robrecht S; Zhang C; Tausch E; Schneider C; Bloehdorn J; Fürstenau M; Dreger P; Ritgen M; Illmer T; Illert AL; Dürig J; Böttcher S; Niemann CU; Kneba M; Fink AM; Fischer K; Döhner H; Hallek M; Eichhorst B; Stilgenbauer S
    Blood; 2022 Mar; 139(9):1318-1329. PubMed ID: 35108374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
    Soumerai JD; Mato AR; Dogan A; Seshan VE; Joffe E; Flaherty K; Carter J; Hochberg E; Barnes JA; Hamilton AM; Abramson JS; Batlevi CL; Matasar MJ; Noy A; Owens CN; Palomba ML; Kumar A; Takvorian T; Ni A; Choma M; Friedman C; Chadha P; Simkins E; Ruiters J; Sechio S; Portman D; Ramos L; Nolet N; Mahajan N; Martignetti R; Mi J; Scorsune K; Lynch J; McGree B; Hughes S; Grieve C; Roeker LE; Thompson M; Johnson PC; Roshal M; Huang J; Biondo J; Wu Q; Jacob A; Abdel-Wahab O; Zelenetz AD
    Lancet Haematol; 2021 Dec; 8(12):e879-e890. PubMed ID: 34826411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.
    Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR
    Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
    Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
    JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
    Tam CS; Allan JN; Siddiqi T; Kipps TJ; Jacobs R; Opat S; Barr PM; Tedeschi A; Trentin L; Bannerji R; Jackson S; Kuss BJ; Moreno C; Szafer-Glusman E; Russell K; Zhou C; Ninomoto J; Dean JP; Wierda WG; Ghia P
    Blood; 2022 Jun; 139(22):3278-3289. PubMed ID: 35196370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
    Al-Sawaf O; Zhang C; Lu T; Liao MZ; Panchal A; Robrecht S; Ching T; Tandon M; Fink AM; Tausch E; Schneider C; Ritgen M; Böttcher S; Kreuzer KA; Chyla B; Miles D; Wendtner CM; Eichhorst B; Stilgenbauer S; Jiang Y; Hallek M; Fischer K
    J Clin Oncol; 2021 Dec; 39(36):4049-4060. PubMed ID: 34709929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.